Biocon Ltd (BIOCON) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Biocon is a global biopharmaceuticals company with biosimilars as its growth engine, reporting into a quarter where the rupee held in the mid-95s against the dollar and generics and biosimilars remained exempt from US pharma tariffs. The print will speak to whether the promised 'meaningful acceleration in the second half of FY27' remains on schedule, and whether biosimilars margins hold near 25% after dipping below the prior 26-28% band.

Biocon Ltd Q2 Results Date and Time

The Board of Biocon Ltd meets on November 4, 2026 to approve the un-audited Q2/H1 FY27 results for the period ended September 30, 2026. The trading window remains closed from October 1 to November 6, 2026 and reopens on November 7.

The earnings call is scheduled for 16:00 IST on November 4, 2026, the same day as the board meeting. No webcast or dial-in link is stated in the intimation.

What to expect from Biocon Ltd's Q2 FY27 results

The dominant question for Q2 FY27 is whether the H2-weighted year management has repeatedly guided to — 'meaningful acceleration in the second half of FY27' — remains on track, with Q2 the last checkpoint before that acceleration must show. The rupee stayed weak in the mid-95s against the dollar through the whole July-September window, so the 'currency advantage in H1' management credited last quarter remained in place, supporting the roughly 75% US/Europe biosimilars mix.

On policy, generics and biosimilars remained exempt from the Section 232 US pharmaceutical tariffs through the quarter, with the exemption regime reaffirmed mid-quarter and the dated cliff being the 2028 generic-tariff step-up, not this quarter. Biosimilars entered Q2 with 16% YoY revenue growth and a 25% EBITDA margin in Q1 — about 200bps below the 26-28% band of the prior three quarters — and management has advised modeling the full-year average margin rather than any single quarter's elevated North America mix.

Generics, which grew 21% YoY in Q1 at a 7% EBITDA margin, sit inside the promised window for gross-margin improvement from recently commissioned facilities, while Syngene remains a transition year with guided single-digit rupee degrowth and EBITDA margins back to the mid-20s from Q1's 12% operating margin. The outcomes of the July-September payor and formulary contracting window for the five key growth products — Aflibercept, Denosumab, Aspart, Ustekinumab and Bevacizumab — were not retrievable from public sources and must be confirmed on the call.

Key Things To Watch

H2-acceleration guidance and contracting outcomes: The key driver of the promised H2 strength is the payor/formulary window that just closed.

• Group momentum guided as 'meaningful acceleration in H2 FY27', with new-launch contribution weighted to H2 and H1 currency advantage — Q2 commentary should confirm whether the H2 ramp remains on schedule
• Payor/formulary outcomes from the July-September contracting window for the five key products (Aflibercept, Denosumab, Aspart, Ustekinumab, Bevacizumab) — the critical window for finalizing contracts for the following calendar year
• Yesafili US launch timing (H2 FY27 / H2 CY2026) and Kirsty commercial expansion in H2 FY27

Biosimilars margin direction

• Biosimilars EBITDA margin of 25% in Q1 FY27, below the 26-28% range of the prior three quarters; management advised modeling full-year average margins
• North America mix commentary — Q3 FY26 NA mix rose to over 46-47% on high-margin market prioritization, versus roughly 40% North America, 35% Europe, 25% Emerging Markets typically

Syngene transition-year guidance

• Guided single-digit revenue degrowth in rupee terms for FY27 and EBITDA margin back to mid-20s; Q1 operating EBITDA margin was 12%
• Watch the 'return to profitable and sustainable growth from FY28' pathway and lower offtake from the key biologics client, plus further forex hedge lines

Generics margin rebuild and interest costs

• Generics EBITDA margin of 7% in Q1 FY27 versus open-ended guidance of improving gross margins (mid-40s in H1 FY26) and an 8-10% R&D trajectory; watch new-facility cost absorption
• Interest costs of Rs. 213 Cr in Q1 FY27 versus the guided Rs. 210-220 Cr/quarter run-rate and ~Rs. 300 Cr annualized savings from FY27
• Whether the inventory build for the H2 scale-up peaked in Q1 — days of inventory outstanding for biosimilars normalized from >400 to 280-290 days

Regulatory and corporate updates

• Pebrilzo EC decision pending following the September 21 EMA CHMP positive opinion; Genentech settlement (Oct 14) secures launch dates of EU/UK Q1 CY2027 and US Q3 CY2028
• Brazil PDP milestone commencement after the consortium received 100% allocation under Brazil's 10-year PDP for Pertuzumab (Sep 8)
• First full quarters of BBL as a wholly owned subsidiary (effective June 29, 2026) and any reporting changes; GST appeal/rectification on the Rs. 3.21 Cr demand order for FY 2022-23; Malaysia insulin drug substance capacity doubling by end FY27